Goldman Sachs tips ResMed shares to rocket 30% to a record high
The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...
Goldman Sachs starts coverage on ResMed with "buy" rating
Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.
Harvard Business Review1d
How Generative AI Improves Supply Chain Management
It can cut decision-making time from days to minutes and dramatically improve results. by Ishai Menache, Jeevan Pathuri, David Simchi-Levi and Tom Linton Companies face a variety of complex ...
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Fintel on MSN6d
Piper Sandler Initiates Coverage of ResMed Inc. - Depositary Receipt () (RSMDF) with Neutral Recommendation
Fintel reports that on January 10, 2025, Piper Sandler initiated coverage of ResMed Inc. - Depositary Receipt () (OTCPK:RSMDF ...
ResMed initiated with a Neutral at Piper Sandler
Piper Sandler initiated coverage of ResMed (RMD) with a Neutral rating and $252 price target While there’s a lot to like about the ResMed ...
Balanced Outlook on ResMed: Strong Execution and Innovations Offset by Valuation Concerns and Market Challenges
Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...